Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. - Wikidata - wikimedia - TriplyDB

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

http://www.wikidata.org/entity/Q35545711

about

Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.Effect of Suo Quan Wan on the bladder function of aging rats based on the β-adrenoceptor.Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology.Recent advances in management of bladder overactivity.Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.Pharmacologic characteristics of bladder micturition function in anesthetized mice Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder Silodosin is effective for treatment of LUTS in men with BPH: a systematic review Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.Silodosin in the treatment of benign prostatic hyperplasia Complex regulation of the TRPM8 cold receptor channel: role of arachidonic acid release following M3 muscarinic receptor stimulation The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.Clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms: a prospective study.Human Urinary Bladder Strip Relaxation by the β-Adrenoceptor Agonist Isoprenaline: Methodological Considerations and Effects of Gender and Age.β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder.Prospective pharmacologic therapies for the overactive bladder Functional and molecular evidence for Kv7 channel subtypes in human detrusor from patients with and without bladder outflow obstruction.Control of urinary drainage and voiding.Bladder dysfunction in diabetes mellitus.α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia Alpha adrenergic receptors in renal pelvis and calyces: can rat models be used?Urinary Bladder Dysfunction in Transgenic Sickle Cell Disease Mice β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase α1-adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta-analysis.Do β3-adrenergic receptors play a role in guinea pig detrusor smooth muscle excitability and contractility?Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms Management of lower urinary tract dysfunction in patients with neurological disorders A single oral dose of Silodosin and Diclofenac sodium is effective in reducing pain after ureteric stent removal: a prospective, randomized, double blind placebo-controlled study.Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors

P2860

Q26825032-418F5DC7-991B-4EAA-9161-7B07F60946D3 Q26864937-29E725A5-C471-4C70-A92C-E7D837E17F09 Q27027373-21327B73-8FCA-40DA-8885-88FDABF29F46 Q33493614-EB5251A7-8FCE-4844-8EF6-3944BEFDC921 Q33744606-67C08700-9665-49AB-AC56-C14178C3A933 Q33838174-883670E2-A309-4FAE-847A-D19FB899C23E Q34019358-25F1F5A1-B054-4A24-B050-5E5FF5F4AE25 Q34062449-253EBF93-A718-4677-BF48-69F16A11CA49 Q34167658-8527CFCA-9F95-44CF-8711-68233F8ED7DC Q34405906-B7363BC2-A8D6-46A0-8BE8-BE94B5C9BECA Q34406969-D4B11A12-0B07-452E-BB65-AB5D514E54CC Q34468669-D5BC3926-1BF3-49B4-AC77-4A2A3468EE09 Q34504207-DEB2C365-BCD3-40AF-837E-41DFAC6E8D24 Q34506119-B6B50A41-9F42-436F-9936-0D71BB9AE3DA Q34585420-DA07CF88-A15B-4925-8F97-B48EDE9CE4A7 Q34625490-B52B04FB-B344-4FD8-BB6A-3A6681801E9A Q34685475-1D838BE0-E2E1-474A-840D-F33A231FF1EC Q34709612-3226CCB9-2D21-4B4B-820C-77B8B6044008 Q34983752-CF6AEC16-3520-4E38-A520-AA514298D7CE Q35025867-AADB2ADB-9DDE-402A-9DEE-975B59A9A6A5 Q35040830-BFD5CC23-CB32-43CD-82F5-38FD1E740B70 Q35076367-D376D68F-5630-4768-8DD8-C3E02775B13C Q35098568-105214C5-DC5B-4D74-9F69-416DCDB13F4F Q35144401-EC4CA609-8B7A-4C6F-A194-92EE8C167404 Q35155238-3F5787A5-85CB-4070-AAE3-5B836C0B2281 Q35183611-8DD83C89-46E7-46AC-86C0-4DEF32B83527 Q35212816-CBAFF611-39AF-4430-8280-0A82913DD8FF Q35512290-1A70E5E4-30A6-4E01-B209-9EFA3CB2781D Q35737367-BA75CB0F-E8CE-4729-B454-FF3EFFC82497 Q35762174-CC06D366-1411-40B1-9DA1-F3662C477614 Q35802642-FBAB78E2-1205-4C4B-ACEF-F298C55860F6 Q35924494-7B2AD333-73EB-446A-8BF8-08747AB95693 Q36024814-89DF6D37-4EFF-46E4-A1E2-8F5350B192E5 Q36133212-656C0E60-9113-45F0-9C70-80DC904B3C57 Q36262124-60E97356-07DD-4D82-8957-07FE9D7F2872 Q36284726-2D9418BF-9DD2-4188-810E-4435752AEB63 Q36441453-BDB32BB9-932C-4F32-BF10-F6EA17637366 Q36506889-0FD69DEC-C096-475E-A372-5170D60ED3FF Q36573132-57062BF7-C0E4-44A3-B4EB-2D08C2B2C83E Q36784801-836969F2-4ED6-4791-8EB1-F32E6C7AB52B

P2860

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

http://www.wikidata.org/entity/Q35545711

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

@ast

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

@en

type

label

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

@ast

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

@en

prefLabel

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

@ast

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

@en

P1433

Q35545711-386A9545-DBC1-486F-85C7-5009C7CE5651

P1476

Q35545711-CE0DAAFD-3D0F-4897-AEC0-4B2B355E8182

P2093

Q35545711-08FB6E8F-8E0C-47B2-AD96-1BF392B64492

Q35545711-9CAEDE8E-ECC8-43DE-94FF-BEA311687604

P2860

Q35545711-032AFF67-EF1C-4129-AA85-F847E3EAEDE0

Q35545711-03D35A98-0E6C-481E-A483-54242CF307CE

Q35545711-0543B5A3-D856-45AB-B5D7-1BD77D0F85A9

Q35545711-06647DBD-67F1-4171-8263-23F886DEEFB4

Q35545711-07608337-4FD8-4A7E-A505-74D6F533F118

Q35545711-08F1F8E7-855B-454A-B463-B19153B36008

Q35545711-092195D7-DA31-4112-A554-7FC601561F75

Q35545711-0A2196E0-B164-4B51-8FAD-6D86C9B3BB37

Q35545711-0C2BF780-647E-479D-B49B-3A0C20CCD574

Q35545711-135FFB2E-E549-46C0-9707-B53E4F76E0B9

P304

Q35545711-AF6C0FC7-D3A9-4388-8B95-F9A043605B1E

P31

Q35545711-090433E4-C552-42E8-8E45-F4F3D1528FF3

P356

Q35545711-99BE7A07-D29D-4408-8897-56CF1E2CD60C

P407

Q35545711-3E1971D1-9C6C-44B6-8A5D-39B95ECB272E

P478

Q35545711-3ECC97CA-6AEE-4DA2-98DF-0A223F5FDE29

P577

Q35545711-A203958F-1B4C-481F-B73C-38379913157F

P5875

Q35545711-BBA47BF3-AF3D-45FA-8833-D437C13909B4

P698

Q35545711-65FDD3D3-14F1-498E-89E9-BD8363C4130A

P932

Q35545711-125BC6EE-1B63-4689-8693-E9CE7B538F54

P356

P1433

British Journal of Pharmacology

P1476

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

@en

P2093

Martin C Michel

http://www.w3.org/2001/XMLSchema#string

Wim Vrydag

http://www.w3.org/2001/XMLSchema#string

P2860

The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype

Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms

Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants

Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor

The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors

The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas

In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists

The role of beta(3)-adrenoceptors in mediating relaxation of porcine detrusor muscle

P304

S88-119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0706619

http://www.w3.org/2001/XMLSchema#string

P407

P478

147 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7309569

http://www.w3.org/2001/XMLSchema#string

P698

16465187

http://www.w3.org/2001/XMLSchema#string

P932

1751487

http://www.w3.org/2001/XMLSchema#string